Provided by Tiger Trade Technology Pte. Ltd.

HBM HOLDINGS-B

16.540
+0.5303.31%
Volume:7.87M
Turnover:130.41M
Market Cap:14.37B
PE:19.18
High:16.950
Open:15.890
Low:15.810
Close:16.010
52wk High:17.980
52wk Low:9.460
Shares:869.00M
HK Float Shares:869.00M
Volume Ratio:1.00
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.862
ROE:37.55%
ROA:14.08%
PB:4.99
PE(LYR):19.18
PS:11.61

Loading ...

Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?

Simply Wall St.
·
2 hours ago

HBM Holdings to Join Hang Seng Composite Index

MT Newswires Live
·
Aug 24

HBM Holdings Added to Hang Seng Composite Index, Enabling Future Stock-Connect Eligibility

Bulletin Express
·
Aug 24

HBM Holdings Surges Nearly 15% as China Approves Clinical Trial Application for Late-Stage Solid Tumor Therapy

Stock News
·
Aug 20

HBM's Cancer Drug Candidate Gets China Approval

MT Newswires Live
·
Aug 18

HBM Holdings Secures NMPA Clearance for HBM7004 IND in Advanced Solid Tumors

Stock News
·
Aug 18

HBM Gets China NMPA Clearance to Start Hbm7004 Trial in Advanced Solid Tumors

Reuters
·
Aug 18

Hbm Holdings - Nmpa Approves Ind Application for Hbm7004 for Advanced Solid Tumors

THOMSON REUTERS
·
Aug 18

HBM Holdings Schedules 27 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 17

HBM Holdings Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 17

HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?

Simply Wall St.
·
Aug 09

Hong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm

Stock News
·
Aug 07

HBM Holdings Adds 0.80 Million Shares from Option Exercises, Lifting Total Issued to 900.98 Million

Bulletin Express
·
Aug 06

Harbour BioMed Names Bob Zhang President of Metabolic Disease Franchise

Reuters
·
Aug 06

Harbour Biomed Appoints DR. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

THOMSON REUTERS
·
Aug 06

Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?

Simply Wall St.
·
Jul 29

HBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body

Stock News
·
Jul 27

Harbour Biomed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

THOMSON REUTERS
·
Jul 27

Hbm Holdings - Enters Strategic Collaboration with China National Pharmaceutical Group on Biologics R&D

THOMSON REUTERS
·
Jul 27

HBM Holdings Enters Strategic Biologics R&D Collaboration with Sinopharm

Reuters
·
Jul 27